Affiliation:
1. Department of Medicine, University of Toronto, Toronto, Canada
2. Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada
Abstract
Neurodegenerative diseases are characterized by the increasing dysfunction and death of
neurons, resulting in progressive impairment of a person’s mobility and/or cognition. Protein misfolding
and aggregation are commonly hypothesized to cause neurotoxicity and, eventually, neuronal
degeneration that are associated with these diseases. Emerging experimental evidence, as well as
recent findings from human studies, reveal that the C-terminus of Hsp70 Interacting Protein
(CHIP), or STIP1 Homology and U-box containing Protein 1 (STUB1), is a quality control protein
involved in neurodegeneration. Here, we review evidence that CHIP interacts with and plays a role
in regulating proteins implicated in the pathogenesis of Parkinson’s disease, Alzheimer’s disease,
amyotrophic lateral sclerosis, and polyglutamine diseases, including Huntington’s disease and
spinocerebellar ataxias. We also review clinical findings identifying mutations in STUB1 as a cause
of both autosomal recessive and autosomal dominant forms of cerebellar ataxia. We propose that
CHIP modulation may have therapeutic potential for the treatment of multiple neurodegenerative
diseases.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology,Neurology,Pharmacology,General Medicine
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献